Frost & Sullivan Independent Equity Research
Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.
![Oramed-Pharmaceuticals-Inc Logo Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/oramed-nx7oenqvj2y33m2uhxiuo5wv2s7xme8mc1ykanhh7c.jpg)
Company: Oramed Pharmaceuticals Inc.
Sector: Pharmaceuticals
Report type: Update for the quarterly period ending 28.2.18
Published on: 26 April, 2018